Logo image of SGMD.CA

SALONA GLOBAL MEDICAL DEVICE (SGMD.CA) Stock Fundamental Analysis

TSX-V:SGMD - TSX Venture Exchange - CA79549X1096 - Common Stock - Currency: CAD

0.21  -0.01 (-2.33%)

Fundamental Rating

2

SGMD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 16 industry peers in the Health Care Equipment & Supplies industry. SGMD has a bad profitability rating. Also its financial health evaluation is rather negative. SGMD shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SGMD had negative earnings in the past year.
SGMD had a negative operating cash flow in the past year.
SGMD had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SGMD reported negative operating cash flow in multiple years.
SGMD.CA Yearly Net Income VS EBIT VS OCF VS FCFSGMD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -23.11%, SGMD is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
SGMD's Return On Equity of -80.88% is fine compared to the rest of the industry. SGMD outperforms 68.75% of its industry peers.
Industry RankSector Rank
ROA -23.11%
ROE -80.88%
ROIC N/A
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-31.22%
ROE(5y)-34.69%
ROIC(3y)N/A
ROIC(5y)N/A
SGMD.CA Yearly ROA, ROE, ROICSGMD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60

1.3 Margins

SGMD has a Gross Margin of 34.23%. This is in the lower half of the industry: SGMD underperforms 62.50% of its industry peers.
In the last couple of years the Gross Margin of SGMD has declined.
The Profit Margin and Operating Margin are not available for SGMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-31.39%
GM growth 5Y-16.71%
SGMD.CA Yearly Profit, Operating, Gross MarginsSGMD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K

More info and screens

1

2. Health

2.1 Basic Checks

SGMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SGMD has more shares outstanding
The debt/assets ratio for SGMD is higher compared to a year ago.
SGMD.CA Yearly Shares OutstandingSGMD.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
SGMD.CA Yearly Total Debt VS Total AssetsSGMD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -0.27, we must say that SGMD is in the distress zone and has some risk of bankruptcy.
SGMD has a better Altman-Z score (-0.27) than 62.50% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that SGMD is somewhat dependend on debt financing.
The Debt to Equity ratio of SGMD (0.83) is worse than 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF N/A
Altman-Z -0.27
ROIC/WACCN/A
WACC9.3%
SGMD.CA Yearly LT Debt VS Equity VS FCFSGMD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.63 indicates that SGMD may have some problems paying its short term obligations.
SGMD has a Current ratio of 0.63. This is in the lower half of the industry: SGMD underperforms 68.75% of its industry peers.
SGMD has a Quick Ratio of 0.63. This is a bad value and indicates that SGMD is not financially healthy enough and could expect problems in meeting its short term obligations.
SGMD has a worse Quick ratio (0.33) than 68.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.33
SGMD.CA Yearly Current Assets VS Current LiabilitesSGMD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for SGMD have decreased by -3.07% in the last year.
Looking at the last year, SGMD shows a very strong growth in Revenue. The Revenue has grown by 137.88%.
The Revenue has been growing by 35.97% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-3.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%117.87%
Revenue 1Y (TTM)137.88%
Revenue growth 3Y144.03%
Revenue growth 5Y35.97%
Sales Q2Q%95.61%

3.2 Future

SGMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.
SGMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 47.41% yearly.
EPS Next Y-50%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year83.45%
Revenue Next 2Y47.41%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SGMD.CA Yearly Revenue VS EstimatesSGMD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SGMD.CA Yearly EPS VS EstimatesSGMD.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 -0.02 -0.04 -0.06

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SGMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMD.CA Price Earnings VS Forward Price EarningsSGMD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMD.CA Per share dataSGMD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as SGMD's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SALONA GLOBAL MEDICAL DEVICE

TSX-V:SGMD (3/20/2024, 7:00:00 PM)

0.21

-0.01 (-2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)01-20 2022-01-20
Inst Owners1.18%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.97M
Analysts80
Price Target1.17 (457.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS1.41
BVpS0.34
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.11%
ROE -80.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.23%
FCFM N/A
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-31.22%
ROE(5y)-34.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-31.39%
GM growth 5Y-16.71%
F-Score4
Asset Turnover1.19
Health
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.24%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.33
Altman-Z -0.27
F-Score4
WACC9.3%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%117.87%
EPS Next Y-50%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)137.88%
Revenue growth 3Y144.03%
Revenue growth 5Y35.97%
Sales Q2Q%95.61%
Revenue Next Year83.45%
Revenue Next 2Y47.41%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1202.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year422.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-283.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.18%
OCF growth 3YN/A
OCF growth 5YN/A